Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.
MedPAC Wrestles With How to Fix Deep Flaws in Medicare Advantage Quality Metrics
The methods used to compare quality between one Medicare Advantage (MA) plan and another are so seriously flawed that the system needs an overhaul, members
March 12, 2024